A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration

• Published in: Ophthalmology (Rochester, Minn.) Vol. 116; no. 9; pp. 1731 - 1739
• Main Authors: Boyer, David S., Heier, Jeffrey S., Brown, David M., Francom, Steven F., Ianchulev, Tsontcho, Rubio, Roman G.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.09.2009; Elsevier
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized; Biological and medical sciences; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Female; Follow-Up Studies; Humans; Injections; Macular Degeneration - complications; Macular Degeneration - drug therapy; Male; Medical sciences; Middle Aged; Miscellaneous; Ophthalmology; Ranibizumab; Retinopathies; Retreatment; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - drug effects; Vitreous Body; Human; Retinopathy; Phase; Toxicity; Monoclonal antibody; Immunomodulator; Eye disease; Vascular endothelium growth factor; Ranibizumab; Age related macular degeneration; Neovascularization; Ophthalmology; Safety; Antiangiogenic agent

To evaluate the safety and efficacy of intravitreal ranibizumab in a large population of subjects with neovascular age-related macular degeneration (AMD). Twelve-month randomized (cohort 1) or open-label (cohort 2) multicenter clinical trial. A total of 4300 subjects with angiographically determined...